Kenneth T. Jones - Sep 12, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role: Vice President, Corporate Controller and Interim Chief Financial Officer
Signature: /s/ Albert P. Parker, Attorney-in-Fact
Stock symbol: ZYNE
Transactions as of: Sep 12, 2023
Transactions value $: -$3,321
Form type: 4
Date filed: 9/14/2023, 04:13 PM
Previous filing: Aug 15, 2023
Next filing: Oct 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award		+9K	+11.39%		88K	Sep 12, 2023	Direct	F1
transaction	ZYNE	Common Stock	Sale	-$3.32K	-2.51K	-2.85%	$1.33	85.5K	Sep 13, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 9,000 performance-based restricted stock awards granted in a prior year.
F2	This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.

Remarks:

Vice President, Corporate Controller and Interim Chief Financial Officer